IONS vs. ALKS, MDGL, FOLD, GERN, UTHR, BMRN, TEVA, ALNY, CYTK, and BPMC
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Geron (GERN), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Cytokinetics (CYTK), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
Alkermes received 7 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 60.16% of users gave Ionis Pharmaceuticals an outperform vote.
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 4.8% of Alkermes shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Alkermes has a net margin of 25.17% compared to Alkermes' net margin of -46.32%. Ionis Pharmaceuticals' return on equity of 20.31% beat Alkermes' return on equity.
Alkermes has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ionis Pharmaceuticals had 6 more articles in the media than Alkermes. MarketBeat recorded 23 mentions for Ionis Pharmaceuticals and 17 mentions for Alkermes. Alkermes' average media sentiment score of 0.57 beat Ionis Pharmaceuticals' score of 0.16 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.
Alkermes has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Alkermes currently has a consensus price target of $35.38, suggesting a potential upside of 46.48%. Ionis Pharmaceuticals has a consensus price target of $57.67, suggesting a potential upside of 41.86%. Given Ionis Pharmaceuticals' higher probable upside, equities analysts plainly believe Alkermes is more favorable than Ionis Pharmaceuticals.
Summary
Alkermes beats Ionis Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
